Key Highlights

  • PAVmed shares rose 9.95% to USD 2.10 in pre-market trading on November 3, 2026.
  • No new announcement explaining the move was found; the most recent release, dated October 30, 2026, set a call date for the third quarter.
  • The third quarter 2026 Business update call is scheduled for November 13, 2026 at 8:30 AM ET.
  • Cash stood at USD 3.8 million on June 30, 2026, versus USD 1.5 million on December 31, 2025.
  • Second quarter 2026 Revenue came in at USD 33 thousand, with a net loss attributable to common stockholders of about USD 5.5 million.

What Drove the Pre-Market Gain in PAVmed Shares (up USD 0.1900, 9.95%)?

PAVmed Inc. (NASDAQ:PAVM) climbed 9.95% to USD 2.10 in pre-market trading on November 3, 2026, compared with the Monday, November 2 close. No company announcement explaining the rise was identified for November 2 or November 3. The latest item is a press release dated October 30, 2026, which fixed the date for the third quarter update. The move therefore appears to reflect momentum or sector trading rather than a response to news.

What Did the Newest Company Release Say?

Per the company press release dated October 30, 2026, PAVmed will host its Third Quarter 2026 business update call on Friday, November 13, 2026, at 8:30 AM ET. Chairman and Chief Executive Officer Lishan Aklog, M.D., will deliver the update, and President and Chief Financial Officer Dennis McGrath will cover financial results.

The notice included no financial results.

What Does PAVmed Do, and How Was Its Latest Quarter?

PAVmed calls itself a diversified, commercial-stage medical technology company spanning devices, diagnostics and digital health. Its subsidiaries include Lucid Diagnostics (NASDAQ:LUCD), which sells the EsoGuard Esophageal DNA Test for early detection of esophageal precancer, and Veris Health, which provides remote monitoring for personalized cancer care.

In its second quarter 2026 report dated August 14, 2026, PAVmed reported revenue of USD 33 thousand, versus USD 6 thousand a year earlier. Operating expenses totaled about USD 7.1 million, and the net loss attributable to common stockholders was about USD 5.5 million, or USD 0.87 per diluted share. Lucid booked USD 1.5 million of EsoGuard revenue and processed 2,770 tests. The company said the Veris implantable monitor is targeting an FDA 510(k) submission in early 2027.

Balance Sheet Strain and Penny Stock Risk

Cash was USD 3.8 million at June 30, 2026, against six-month operating expenses of USD 15.1 million, so the company relies on raising further funding, a risk it notes in its filings. Calculated from those figures, cash covers roughly one quarter of spending at the first-half pace. Penny stocks like this one are prone to sharp swings, thin trading and possible dilution if new Equity is issued.

What Investors Should Track Next

The key date is the November 13, 2026 call, where management is expected to address third quarter results, cash, funding plans and EsoGuard testing and coverage. Investors may also look for updates on the Veris monitor submission and the PortIO FDA meeting request planned for the fourth quarter of 2026.